Estrella Immunopharma, Inc.

ESLA · XNAS

CIK 1844417fmd_1PMRP0C8J1SYXEHQAK694VHCYYManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 06, 2021 to Jun 30, 2026, 22 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.